SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BKYI reported Q3 2026 results. The price and volatility reaction is pending.
BKYIearnings

Earnings reactions, page 2

BIO-key International, Inc. (BKYI) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Q3’26 total revenues were $1,482,781 compared to $1,549,706 in Q3’25.
  • Q3’26 license fee revenue rose 39% to $1,275,249 compared to $917,951 in Q3’25.
  • Q3’26 gross profit was $1,339,408 with a gross margin of 90%, compared to gross profit of $1,191,718 and a gross margin of 77% in Q3’25.
  • Q3’26 net loss was $(886,083) compared to $(964,849) in Q3’25.
  • Q3’26 net loss available to common stockholders was $(5,388,087), or $(4.01) per basic and diluted share, compared to $(964,849), or $(1.44) per basic and diluted share, in Q3’25.
  • 9M’26 total revenues increased 14% to $5,548,305 compared to $4,853,772 in 9M’25.

Guidance

  • BIO-key anticipates a solid finish to 2026 and a strong start to 2027, supported by recent Middle East government wins, a growing pipeline of government and financial sector opportunities, expanding deployments with existing customers, and anticipated annual license renewals.

Notes

Per share amounts and weighted average common shares outstanding for all periods reflect a 1-for-10 reverse stock split effective April 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →